|
 |
|
|
|
Tekmira Pharmaceuticals Corporation
 |
Type of Company: |
Tech Company
|
Ownership: |
Publicly Traded (TKMR, NASDAQ) |
Company Size: |
74 Employees In BC (74 Total) |
Revenue: |
$21.40 Million CAD |
Year Founded: |
1992 |
Sector: |
Biotech/Life Sciences |
Region: |
Lower Mainland / South Coast
|
Tags: |
therapeutics, development, gene silencing, RNAi, genetics
|
|
 |
|
As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.
Tekmira is uniquely equipped to become a force in this field. Guided by a cohesive vision, the Company possesses leading technology capabilities and a solid intellectual property portfolio in the area of using lipid nanoparticle (LNP) technology to deliver siRNA (small interfering RNA) as well as other nucleic acids in the treatment of disease.
Read more about how Tekmira is developing its own RNAi product candidates. In addition, Tekmira has fostered collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck. Read more about Tekmira's partnerships.
|
|
|
|
|
 |
Date |
Type |
Amount |
Investors |
|
|
 |
100-8900 Glenlyon Parkway
Burnaby, BC
V5J 5J8
Canada [ MAP ]
|
|
|
|
1 - 10 of 64 results
|
|
 |
|
 |
|
May 16, 2012
|
Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
|
|
Mar 28, 2012
|
Tekmira Provides Corporate Update and Announces 2011 Results
|
|
Mar 22, 2012
|
Tekmira Provides Update on Licensed Product Candidate, Marqibo
|
|
Mar 1, 2012
|
Tekmira Expands Product Pipeline with RNAi Therapeutic for the Treatment of Alcohol Dependence
|
|
Feb 9, 2012
|
Tekmira Announces USPTO Issuance of Key Patents
|
|
Feb 8, 2012
|
Tekmira Announces Initiation of TKM-Ebola Phase 1 Clinical Trial
|
|
Dec 22, 2011
|
Tekmira Secures $3 Million Financing
|
|
Nov 28, 2011
|
Tekmira Pharmaceuticals Receives Approval From FDA to Initiate TKM-Ebola Phase 1 Clinical Trial
|
|
Nov 21, 2011
|
Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data
|
|
Nov 9, 2011
|
Tekmira Provides Corporate Update and Announces Third Quarter 2011 Results
|
|
|
1 - 10 of 64 results
|
|
|
|
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
|
|
|
© 2012 T-Net. All Rights Reserved. |